Parents united to find a cure
  • Home
  • About Us
    • Mission Statement
    • Our Goal
    • Board of Directors
    • Scientific and Research Advisory Board
    • Strategic Plan
    • Financial Statement
    • What is Sanfilippo Syndrome?
    • Contact Us
  • How You Can Help
    • Donate
    • Host or Attend an Event
    • Products and New Items for sale to promote awareness and serve families!
    • Become an Affiliate
      • Spinning Wheels Productions and Team Sanfilippo Collaboration
  • Research
    • Research Projects
      • Research – Australia
      • Research – Canada
      • Research – France and Netherlands
      • Research – Italy
      • Research – Poland
      • Research – Spain
      • Research – United Kingdom
      • Research – United States
    • Request for Proposals
  • Therapies and Upcoming Treatments
  • Grants
  • News
    • Gene Therapy
    • Press Releases
    • Community News
    • Resource Links
  • Events

Research Projects – United Kingdom

February 15, 2012 by Team Sanfilippo

Intrathecal Enzyme Replacement Therapy Sanfilippo A

Shire Human Genetics
Dr. Simon Jones
Dr. Frits Wijberg

A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan N-Sulfatase (rhHNS) Intrathecal Administration Via an Intrathecal Drug Delivery Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Shire Human Genetic Therapies (Shire HGT) is developing a sulfamidase enzyme replacement therapy (ERT)rhHNS for patients with MPS IIIA. rhHNS is being administered into the cerebrospinal fluid (CSF) via a surgically implanted intrathecal drug delivery device (IDDD).

This study is a multicenter, multiple-dose, dose escalation study designed to evaluate the safety, tolerability, and clinical activity of up to 3 dose levels (2 doses [10 and 45mg] monthly and 1 dose [45mg] every other week for 6 months) of rhHNS administered via an IDDD in patients with Sanfilippo syndrome Type A ages greater than or equal to 3 years of age.

The phase I/II clinical trial is planning to enroll 15 patients, beginning June 2010. The study is expected to be completed March 2012, and the duration of the study for each patient is nine months.

The Phase I / II clinical study is being conducted at two sites:

  • Emma Children’s Hospital, Academic Medical Center in The Netherlands by Dr. Frits Wijberg
  • St. Mary’s Hospital in Manchester, UK under the direction of Drs. Simon Jones and Ed Wraith.

Additional information about the clinical trial can be obtained at www.clinicaltrials.gov (Identifier: NCT01155778) or by contacting Tiffany Crump 484-595-8257, tcrump@shire.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it or Daryll Heron +44 1256 894572, dheron@shire.com.

How You Can Help

There are many ways you can get involved in the great work of our organization:
  • Host or Attend an Event
  • Become an Affiliate
  • Make a Donation

Donate using PayPal or Credit Card

Donate using Network for Good

Learn More About Team Sanfilippo

Team Sanfilippo Foundation Brochure

To view the Team Sanfilippo Foundation Brochure click here.

Join Team Sanfilippo & Follow Us

Return to top of page
Site Map
© 2025 Team Sanfillipo • Log in